Vetio Awarded Cannabis Research License, Begins Cannabis-Based Vet Drug Products

Listen to this article

Press release: Vetio

Vetio, a contract development and manufacturing organization dedicated to Animal Health, has been issued a cannabis research license by Health Canada under the Cannabis Act and Cannabis Regulations.

John Kane, CEO of Vetio, commented, “With this license, we are now able to bring Vetio’s expertise to the emerging field of therapeutic cannabis-based products. We believe that cannabis-based products will be vital to Animal Health, and Vetio is committed to bring solutions to our global partners that are based on science and a disciplined development approach.”

Vetio is uniquely positioned to advance innovation within the category by leveraging key enabling technologies, including palatability and taste-masking, controlled-release techniques, and intellectual property in pharmaceutical-grade soft chews. The soft chew technology yields a highly palatable and stable drug format uniquely suited for cannabis-based ingredient delivery.

“This is an important step in expanding our strategic Cannabis initiative to our full North American footprint, and is aligned with our mission of improving the lives of animals while assuring compliance of products to the highest industry standards,” said Mike Smith, vice president of Business Development. “With Cannabis R&D now in Montreal, our Jupiter, FL facility will remain focused on the development and manufacturing of Hemp-derived CBD liquid supplements and infused topical products.” 

Vetio has a long history of veterinary drug development and analytical method expertise, with nearly 40 scientists and engineers assisting clients in the registration and approval of novel and generic drug products through Health Canada, the FDA and other agencies around the world. In addition to the soft chews, Vetio recently expanded its Montreal manufacturing capabilities for tablets, liquids, primary and secondary packaging, complex intermediate drug processing and palatants.  Contract manufacturing at the Jupiter facility is dedicated to non-sterile topicals, otics, oral care and supplements for the companion, small animal and equine markets.